BenevolentAI starts AI collaboration with AstraZeneca to accelerate drug discovery

BenevolentAI is an AI company where AI actually means something. Founded in 2013, it focuses on “accelerating the journey from data to medicines.” To achieve that, it has raised a whopping $202 million to look at early drug discovery through to late-stage clinical development, and has a research facility in Cambridge, U.K. where there is … Continue reading BenevolentAI starts AI collaboration with AstraZeneca to accelerate drug discovery